Urogynäkologie im Alter

Werner Bader, Jasmin Kimmel

 

  1. Sykes D, Castro R, Pons ME: Characteristics of female outpatients with urinary incontinence participating in a 6-month  observational study in 14 European countries. Maturitas 2005; 52 (Suppl) S13–S23
  2. Subak LL, Whitcomb E, Shen H, Saxton J, Vittinghoff E, Brown JS. Weight loss: A novel and effective treatment for urinary incontinence. The Journal of urology. 2005;174:190-195
  3. Jurczak I, Chrzeszczyk M. [the impact assessment of pelvic floor exercises to reduce symptoms and  quality of life of women with stress urinary incontinence]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 2016;40:168-172
  4. Engberg S, Sereika SM. Effectiveness of pelvic floor muscle training for urinary incontinence: Comparison within and between nonhomebound and homebound older adults. Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society / WOCN. 2016;43:291-300
  5. Hirakawa T, Suzuki S, Kato K, Gotoh M, Yoshikawa Y. Randomized controlled trial of pelvic floor muscle training with or without biofeedback for urinary incontinence. International urogynecology journal. 2013;24:1347-1354
  6. Fitz FF, Resende AP, Stupp L, Costa TF, Sartori MG, Girao MJ, Castro RA. [effect the adding of biofeedback to the training of the pelvic floor muscles to treatment of stress urinary incontinence]. Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia. 2012;34:505-510
  7. Trivedi D. Cochrane review summary: Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women. Primary health care research & development. 2015;16:545-547
  8. Richmond CF, Martin DK, Yip SO, Dick MA, Erekson EA. Effect of supervised pelvic floor biofeedback and electrical stimulation in women with mixed and stress urinary incontinence. Female pelvic medicine & reconstructive surgery. 2016
  9. Tenfelde S, Tell D, Thomas TN, Kenton K. Quality of life in women who use pessaries for longer than 12 months. Female pelvic medicine & reconstructive surgery. 2015;21:146-149
  10. Weber MA, Kleijn MH, Langendam M, Limpens J, Heineman MJ, Roovers JP. Local oestrogen for pelvic floor disorders: A systematic review. PloS one. 2015;10:e0136265
  11. Chen CC, Collins SA, Rodgers AK, Paraiso MF, Walters MD, Barber MD. Perioperative complications in obese women vs normal-weight women who undergo vaginal surgery. American journal of obstetrics and gynecology. 2007;197:98 e91-98
  12. Stepp KJ, Barber MD, Yoo EH, Whiteside JL, Paraiso MF, Walters MD. Incidence of perioperative complications of urogynecologic surgery in elderly women. American journal of obstetrics and gynecology. 2005;192:1630-1636
  13. Toglia MR, Nolan TE. Morbidity and mortality rates of elective gynecologic surgery in the elderly woman. American journal of obstetrics and gynecology. 2003;189:1584-1587; discussion 1587-1589
  14. Munro J, Booth A, Nicholl J. Routine preoperative testing: A systematic review of the evidence. Health Technol Assess. 1997;1:i-iv; 1-62
  15. Callaghan LC, Edwards ND, Reilly CS. Utilisation of the pre-operative ecg. Anaesthesia. 1995;50:488-490

Hormone in der Urogynäkologie – ein update

Gerlinde Debus    

 

  1. de Lancey JOL et al Casual factors for Pelvic Floor Disorders: in integrated Lifespan-Model. Am J Obstet Gynecol 2008 199:616e1-616 e6 
  2. Connell KA, Guess MK, Chen H, Andikyan V, Bercik R, Taylor HS. HOXA11 is critical for development and maintenance of uterosacral ligaments and deficient in pelvic prolapse. J Clin Invest. 2008 Mar;118(3):1050-5. doi: 10.1172/JCI34193.
  3. Zong W, Stein SE, Starcher B, Meyn LA, Moalli PA. Alteration of vaginal elastin metabolism in women with pelvic organ prolapse. Obstet Gynecol. 2010 May;115(5):953-61. doi: 10.1097/AOG.0b013e3181da7946.
  4. Wen Y, Ho JY, Polan ML, Chen B. Expression of apoptotic factors in vaginal tissues from women with urogenital prolapse. Neurourol Urodyn. 2011 Nov;30(8):1627-32. doi: 10.1002/nau.21127. Epub 2011 Jun 14.
  5. Wu JM, Visco AG, Grass EA, Craig DM, Fulton RG, Haynes C, Weidner AC, Shah SH.Matrix metalloproteinase-9 genetic polymorphisms and the risk for advanced pelvic organ prolapse. Obstet Gynecol. 2012 Sep;120(3):587-93. doi: 10.1097/AOG.0b013e318262234b.
  6. Wang S, Zhang Z, Lü D, Xu Q. Effects of mechanical stretching on the morphology and cytoskeleton of vaginal fibroblasts from women with pelvic organ prolapse. Int J Mol Sci. 2015 Apr 27;16(5):9406-19. doi: 10.3390/ijms16059406.
  7. Goldstein I, Dicks B, Kim NN, Hartzell R.Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women. Sex Med. 2013 Dec;1(2):44-53. doi: 10.1002/sm2.17.
  8. Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014 Dec;124(6):1147-56. doi: 10.1097/AOG.0000000000000526
  9. Rahn DD, Ward RM, Sanses TV, Carberry C, Mamik MM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int Urogynecol J. 2015 Jan;26(1):3-13. doi: 10.1007/s00192-014-2554-z. Epub 2014 Nov 13. 
  10. Lüthje P, Hirschberg AL, Brauner A. Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas. 2014 Jan;77(1):32-6. doi: 10.1016/j.maturitas.2013.10.018. Epub 2013 Nov 5.
  11. Cardozo L, Lose G, McClish D, Versi E, de Koning Gans H. A systematic review of estrogens for recurrent urinary tract infections: third report of the hormones and urogenital therapy (HUT) committee. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12(1):15-20. PMID: 11294525
  12. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012 Oct 17;10:CD001405. doi: 10.1002/14651858.CD001405.pub3. Review. PMID: 23076892
  13. Weber MA, Kleijn MH, Langendam M, Limpens J, Heineman MJ, Roovers JP. Local Oestrogen for Pelvic Floor Disorders: A Systematic Review. PLoS One. 2015 Sep 18;10(9):e0136265. doi: 10.1371/journal.pone.0136265. eCollection 2015.
  14. Abdelbary AM, El-Dessoukey AA, Massoud AM, Moussa AS, Zayed AS, Elsheikh MG, Ghoneima W, Abdella R, Yousef M. Combined Vaginal Pelvic Floor Electrical Stimulation (PFS) and Local Vaginal Estrogen for Treatment of Overactive Bladder (OAB) in Perimenopausal Females. Randomized Controlled Trial (RCT). Urology. 2015 Sep;86(3):482-6. doi: 10.1016/j.urology.2015.06.007. Epub 2015 Jun 30.

10 Jahre HPV-Impfung

Michael Wojcinski

 

  1. Göttinger gelehrte Anzeigen unter der Aufsicht der königl. Gesellschaft der Wissenschaften, 80. Stück, Den 21. May 1831, S.791
  2. Ruge, Carl Arnold & Veit, Johann: Anatomische Bedeutung der Erosionen am Scheidentheil. Zbl. Gynäk., 1. – 1877
  3. Hinselmann, Hans, Verbesserung der Inspektionsmöglichkeit von Vulva, Vagina und Portio, Münchner Medizinische Wochenschrift ,72. Jahrgang II. Hälfte, 1925
  4. G. N. Papanicolaou, New Cancer Diagnosis.  Proceedings of the Third Race Betterment Conference, January 2-6. 1928. 1928: 528-534
  5. zur Hausen. H.: Papillomavirus infect ions - a major cause of human cancers. Biochem. Biophys. Acta, Rev. on Cancer 1288 ( 1996) F55 - F78.
  6. Schiller JT, Davies P. Delivering on the promise: HPV vaccine and cervical cancer. Nature Rev. 22, 343–347 (2004).
  7. Fachinformation Gardasil
  8. Empfehlung der STIKO zur HPV-Impfung (Stand: März 2007) Robert Koch Institut, Epidemiologisches Bulletin, 23. März 2007 / Nr. 12
  9. Fachinformation Cervarix
  10. Impfquoten der Masern-, HPV- und Influenza-Impfung in Deutschland, Robert Koch Institut, Epidemiologisches Bulletin, 11. Januar 2016 / Nr. 1
  11. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen vom 02.09.1993; Stand: 01.01.2016,  Impfempfehlung E 1,
  12. Pressemitteilung der European Medicines Agency (EMA) vom 5.11.2015
  13. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723.
  14. Safety and Tolerability of a Novel 9-Valent HPV Virus-Like Particle Vaccine Moreira , Joura , Van Damme , Schilling, Kosalaraksa,  Uva, Martin, and Luxembourg on behalf of the V503 investigators
  15. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009; 302(7):750-7
  16. Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, et al. ; Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct; 29(46):8279-84.
  17. Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, et al.; Safety of quadrivalent human papillomavirus vaccine administered routinely to females.  Arch Pediatr Adolesc Med. 2012 Dec; 166(12):1140-8..
  18. Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, et al.; Surveillance of autoimmune conditions following routine use of quadrivalent  human papillomavirus vaccine.  J Intern Med. 2012 Feb; 271(2):193-203. Epub 2011 Nov.
  19. Grimaldi-Bensouda L, Guillemot D, Godeau B, Benichou J, Lebrun-Frenay C, Papeix C, et al. ;      Autoimmune disorders and quadrivalent human papillomavirus vaccination of  young female subjects. J Intern Med. 2014 Apr; 275(4):398-408. Epub 2013 Nov 22.
  20. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. ;  Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: Cohort study.  BMJ. 2013 Oct;347:f5906.
  21. CDC: Frequently Asked Questions about HPV Vaccine Safety: 16 Meldungen  einer POI nach Gardasil-Impfung; 10 Meldungen über ovarielle Hormonstörungen ; CDC and FDA haben keinen Zusammenhang zwischen einer Gardasilimpfung und einer primären Ovarialinsuffizienz bestätigen können
  22. Scheller NM, Svanström H, Pasternak B, Arnheim-Dahlström L, Sundström K,  Katharina Fink K, et al. ;  Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015 Jan; 313(1):54-61..
  23. Moro PL, Zheteyeva Y, Lewis P, Shi J, Yue X, Museru OI, et al. ; Safety of quadrivalent human papillomavirus vaccine (Gardasil®) in pregnancy:  Adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.  Vaccine. 2015 Jan; 33(4): 519-22.
  24. Pharmacovigilance Risk Assessment Committee der EMA; EMA-Statement: Bewertung aller Meldungen zu POTS und CRPS zeigen eindeutig, dass HPV-Impfungen nicht die Ursache sind.  05.11.2015
  25. Bulletin zur Arzneimittelsicherheit;  Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) und Paul Ehrlich Institut (PEI), Ausgabe 1,  März 2013
  26. VAERS(http://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html) Juni 2006 –Sept. 2015 
  27. Denny L; International Federation of Gynecology and Obstetrics ; Int J Gynaecol Obstet.; Safety of HPV vaccination: a FIGO statement;  2013 Dec;123(3):187-8. doi: 10.1016/j.ijgo.2013.09.009. Epub 2013 Sep 13.
  28. Official Statement concerning HPV Vaccine Safety of the International Papillomavirus Society, the Worldwide Organisation of Papillomavirus Experts ;MInternational Papillomavirus Society. Available from: www.ipvsoc.org.
  29. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK : The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011 Dec;87(7):544-7. doi: 10.1136/sextrans-2011-050234. Epub 2011 Oct 4.
  30. Fachinformation Gardasil , April 2016
  31. Fachinformation Gardasil 9, 26.April 2016
  32. Susanne Hartwig, Stina Syrjänen, Géraldine Dominiak-Felden, Maria Brotons and Xavier Castellsagué: Estimation of the epidemiological burden of human papillomavirus-related cancers and nonmalignant diseases in men in Europe; BMC Cancer 2012, www.biomedcentral.com/1471-2407/12/30   
  33. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML: Human papillomavirus and rising oropharyngeal cancer incidence in the United States; J Clin Oncol. 2011 Nov 10;29(32):4294-301. doi: 10.1200/JCO.2011.36.4596. Epub 2011 Oct 3.
  34. McKee SJ, Bergot AS, Leggatt GR. Recent progress in vaccination against human papillomavirus-mediated cervical cancer, Rev.Med. Virol. 25, 54–71 (2015).

Das Mikrobiom und die Immunentwicklung der Neugeborenen

Helmut Jäger

 

  1. ASM 2014: American Society of Microbiology: FAQ Microbiome 2014 academy.asm.org/index.php/faq-series/5122-humanmicrobiome
  2. Jones ML et al. Emerging science of the human microbiome. Gut Microbes 2014, Jul 11; 5(4).
  3. Rajjili?-Stojanovi? M et al. Long-term monitoring of the intestinal microbiota composition. Environ Microbiol 2013, 15:1146–1159.
  4. Meadow J et al. Humans differ in their personal microbial cloud. Peer J 2015 Sep 22; 3:e1258.
  5. Chuong et al. 2016
  6. Scarpellini E et al. The human gut microbiota and virome: Potential therapeutic implications. Dig Liver Dis 2015, 47(12):1007–12.
  7. Ogilvie L, Jones BV. The human gut virome: a multifaceted majority. Front Microbiol 2015, 6:918.
  8. van der Burgh R et al. Mitochondria in autoinflammation: cause, mediator or bystander? Trends Endocrinol Metab 2015 Apr 4. pii: S1043–2760(15)00048–X.
  9. Wang CH et al. Oxidative stress response elicited by mitochondrial dysfunction: implication in the pathophysiology of aging. Exp Biol Med 2013 May; 238(5):450–60.
  10. Saint-Georges-Chaumet Y et al. Microbiota-mitochondria inter-talk: consequence for microbiota-host interaction. Pathog Dis 2015, Oct 23; pii:ftv096.
  11. Carabotti M. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Annals of Gastroenterology 2015; 28:203–9.
  12. Belkaid Y et al. Role of the Microbiota in Immunity and Inflammation. Cell 2014; 157:121–141. 
  13. Kernbauer E et al. An enteric virus can replace the beneficial function of commensal bacteria. Nature 2014 Dec 4; 516(7529):94–8.
  14. Coyte KZ. The ecology of the microbiome: Networks, competition, and stability. Science 2015 Nov 11; 350(6261):663–66.
  15. Relman DA. The Human Microbiome and the Future Practice of Medicine. JAMA 2015; 314(11):1127–28. 
  16. Fernández l et al. The human milk microbiota: origin and potential role in health and disease. Pharmacological Research 2013; 69:1–10.
  17. Chu D  & Aagaard KM. Microbiome: Eating for trillions. Nature 2016 Apr 21; 532(7599):316–7.
  18. Aagaard K et al. A Metagenomic Approach to Characterization of the Vaginal Microbiome Signature in Pregnancy. PLOS One 2012; 7(6):e36466.
  19. Kaiser J. Gearing up for a closer look at the human placenta. Science 2014; 344(6188):1073.
  20. Douvier, S. et al. Chorioamnionitis with intakt membranes caused by Capnoytophaga sputigena. Eur J Obst Gyn Reprod Biol 1999; 83(1):109–12.
  21. Bearfield, C. et al. Possible association between amniotic fluid micro-organism infection and microflora in the mouth. BJOG 2002; 109(5):527–33.
  22. Witkin SS. The vaginal microbiome, vaginal anti-microbial defence mechanisms and the clinical challenge of reducing infection-related preterm birth. BJOG 2015; 122:213–19.
  23. Fernandéza et al., 2012
  24. Jeurink P.V. et al. Human milk: a source of more life than we imagine. Beneficial Microbes 2013; 4(1):17–30. 
  25. Matteoli, G. et al. The vagal innervation of the gut and the immune homeostasis. Gut 2013 Aug; 62(8):1214–22. 
  26. Maynard C et al. Reciprocal interactions of the intestinal microbiota and the immune system. Nature Review 2012; 489:231–41.
  27. Belzer C et al. Dynamics of the Microbiota in Response to Host Infection. PLoS One 2014 Jul 11; 9(7):e95534.
  28. Morrow, A. Earlymicrobial and metabolic signatures predict later onset of necrotising enterocolitis in preterms infants. Microbiome 2013 Apr 16; 1(1):13.
  29. Prince, A. L. et al. The Microbiome and Development: a mothers perspective. Semin Reprod Med 2014; 32:14–22.
  30. LaTunga, M. S. et al. A Review of the Source and Function of Microbiota in Breast Milk. Semin Reprod Med 2014; 32:68–78.
  31. Faa G et al. Fetal programming of the human brain: is there a link with insurgence of neurodegenerative disorders in adulthood? Curr Med Chem 2014; 21(33):3854–76.
  32. Praveen P et al. The role of breast-feeding in infant immune system: a systems perspective on the intestinal microbiome. Microbiome 2015; 3(1):41.
  33. Turfkruyer M et al. Breast milk and its impact on maturation of the neonatal immune system. Curr Opin Infect Dis 2015 Jun; 28(3):199–206.
  34. Gustavson M et al. Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome medicine 2014, 6:82.
  35. Daley D. The evolution of the hygiene hypothesis: the role of early-life exposures to viruses and microbes and their relationship to asthma and allergic diseases. Curr Opin Allergy Clin Immunol 2014 Oct; 14(5):390–96. 
  36. Abrahamson TR et al. Low gut microbiota diversity in early infancy precedes asthma in school age. Clin Exp Allergy 2014; 44:842–50.
  37. Strachan DP. Hay fever, hygiene and household size. DMJ 1989; 299:1259–60.
  38. Vieira SM. Diet, Microbiota and Autoimmune Diseases. Lupus 2014 May; 23(6):518–26.
  39. Ash C et al. Manipulating the microbiota. Science 2016 Apr 29; 352(6285):530–31.
  40. O’Mahony SM et al. Early-life adversity and brain development: Is the microbiome a missing piece of the puzzle? Neuroscience 2015; pii: S0306-4522(15)00895–7.
  41. Rogers G. Germs and joints: the contribution of the human microbiome to rheumatoid arthritis. Nature Medicine 2015; 21(8):839–41.
  42. Foster JA et al. Gut microbiota and brain function: An evolving field in neuroscience. Int J Neuropsychopharmacol 2015 Oct 4; pii:pyv114. 
  43. Dinan TG et al. The impact of gut microbiota on brain and behaviour: implications for psychiatry. Curr Opin Clin Nutr Metab Care 2015; 18(6):552–58.
  44. Jäger H. Fetale Herzsteuerung: Reflexhaft und chaotisch. DHZ 2014, 11:38–43; Mütterliche Mikroflora. DHZ 2014, 2:67–71; Das Mikrobiom des Menschen. DHZ 2016, 68(2):79.
  45. Wekerle 2015. Vortrag auf dem 88. Kongress der Deutschen Gesellschaft für Neurologie (DGM, Düsseldorf); GGN Pressemitteilung. Vorliegende Publikation: Hohlfeld R, Wekerle H. Multiple Sklerose und Mikrobiota Vom Genom zum Metagenom? Der Nervenarzt 2015 Aug; 86(8):925–33.
  46. Haghikia A et al. Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine. Immunity 2015 Oct 20; 43(4):817–29. 
  47. Eisenstein M. Bacterial Broadband. Nature 2016; 533:104–5.
  48. De Palma G et al. The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? J Physiol 2014 Jul 15; 592(Pt 14):2989–97.
  49. Sherman MP et al. Gut microbiota, the immune system, and diet influence the neonatal gut-brain axis. Pediatr Res 2015 Jan; 77(1-2):127–35.
  50. Gensollen et al. How colonization by microbiota in early life shapes the immune system. Science Apr 29; 352(6285): 539–44.
  51. Cox L et al. Altering the Intestinal Microbiota during a Critical Developmental Window Has Lasting Metabolic Consequences. Cell 2014; 158(4):705–21.
  52. Dinsmoor, M.J. et al. Use of intrapartum antibiotics and the incidence of postnatal maternal and neonatal yeast infections. Obstetrics and gynecology 2005; 106(1):19–22.
  53. Stokholm, J. et al. Antibiotic use during pregnancy alters commensal vaginal microbiota, Clin Microbiol Infect 2014 Jul; 20(7):629–35.
  54. Blaser M. Antibiotic use and its consequences for the normal microbiome. Science 2016; 352(6285):344–55.
  55. Azad MB et al. Infant antibiotic exposure and the development of childhood overweight and central adiposity. Int J Obes 2014 Oct; 38(10):1290–98.
  56. Arrieta MC et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Science Translational Medicine 2015 Sep 30; 7(307):307ra152.
  57. Cho I et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012; 488:621–26.
  58. Pamer E. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 2016 Apr 29; 352(6285):535–38.
  59. Polin, R. et al. Management of Neonates with Suspected or Proven Early-Onset Bacterial. Pediatrics 2012; 129:1006.
  60. Berger et al. Empfehlungen zur Prävention und Therapie von Termin- und knapp frühgeborenen Kindern (> 34 SSW) mit erhöhtem Risiko einer perinatalen bakteriellen Infektion (early-onset Sepsis). Revidierte Empfehlungen der Schweizerischen Gesellschaft für Neonatologie in Zusammenarbeit mit der Pädiatrischen Infektiologiegruppe Schweiz (PIGS). Pediatrica 2013; 24(1):11–13.
  61. Halis H. In the diagnosis of neonatal sepsis importance of gelsolin and relationship with mortality and morbidity. Medical Hypothesis 2016 Sep; 94:77–80. 
  62. Shubin, N. J. Anti-Inflammatory Mechanisms of Sepsis. In: Herwald, H. (Hrsg.): Sepsis – Pro- Inflammatory and Anti- Inflammatory Responses. Contrib Microbiol 2011; Karger, Basel (Hrsg.); 17:108–24.
  63. Shah, B. et al. Neonatal sepsis. An old problem with new insights. Virulence 2014; 5(1):170–78.
  64. Vincent, J. L. et al. Sepsis definitions: time for change. Lancet 2013; 381:774–75.
  65. Castellheim, A. et al. Innate Immune Responses to Danger Signals in Systemic Inflammatory Response Syndrome and Sepsis. Scandinavian Journal of Immunology 2009; 69:479–91.
  66. Crea, P. et al. Innate immune inflammatory response to danger: when, how, and why does a friend become a foe? Eur Heart J 2012; 33(12):1434–37.
  67. Trend St et al. Levels of innate immune factors in preterm and term mothers’ breast milk during the 1st month postpartum. British Journal of Nutrition 2016; 115:1178–93.
  68. Mueller et al. The infant microbiome development: mom matters, Trends in Molecular Med 2015; 21(2):109–17. 
  69. AWMF-Leitlinie: Prophylaxe der Neugeborenensepsis - frühe Form - durch Streptokokken der Gruppe B. Registernummer 024/020, Stand: 09.03.2016, gültig bis 08.03.2021. 
  70. Flügge K. et al. Incidence and Clinical Presentation of Invasive Neonatal Group B Streptococcal Infections in Germany. Pediatrics 2006; 117(6):e1139–45.
  71. Flügge K. et al. Genetic Differences Between Invasive and Noninvasive Neonatal Group B Streptococcal Isolates. The Pediatric Infectious Disease Journal 2011; 30(12):1027–31.
  72. Ohlsson, A. et al. Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev 2013 Jan 31; (1):CD007467.
  73. Young, B. C. et al. Evaluation of a rapid, real-time intrapartum group B streptococcus assay. Am J Obstet Gynecol 2011; 205(4):372.
  74. RCOG (Royal College of Ostetricians and Gynaecologists) Green–top Guideline No. 36, Stand 18.07.2012 (aktualisiert im Dezember 2014).
  75. Neu J. The microbiome during pregnancy and early postnatal life. J Semin Fetal Neonatal Med 2016 Jun 7; pii: S1744–165X(16)30015–4.
  76. Rautava S. Early microbial contact, the breast milk microbiome and child health. J Dev Orig Health Dis 2016 Feb; 7(1):5–14. 

Antibiotika bei Harnwegsinfektionen

Elke Heßdörfer

 

  1. AWMF-Leitlinie Harnwegsinfektionen bei Erwachsenen, unkompliziert bakteriell ambulant erworben: Epidemiologie, Diagnostik, Therapie und Management 
  2. R. Pickard (Chair), R. Bartoletti, T.E. Bjerklund-Johansen, G. Bonkat, F. Bruyère, M. Çek, M. Grabe, P. Tenke, F. Wagenlehner, B. Wullt, EAU – Guideline Urological Infections 2016
  3. Brumbaugh, A. R., & Mobley, H. L. . Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Review of Vaccines, 2012,11(6), 663–676. 
  4. G Schmiemann, J Noll, F Hoffmann, Resistenzprüfung bei Harnwegsinfektionen, Urologe 2016 (55) ;514-519
  5. C Jernberg, S Löfmark, C Edlund, J K Jansson, Long-term impacts of antibiotic exposure on the human intestinal microbiota, Microbiology 2010, 156, 3216-3223
  6. C Edlund, C E Nord, Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections, J Antimicrobial Chemotherapy 2000 , 46; Suppl. S1, 41-48
  7. L Dethlefsen, D A Relman, Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation, PNAS 2011, 108; 4554-4561
  8. B Ragnarsdóttir, K Jönsson , A Urbano, J Grönberg-Hernandez, N Lutay, M Tammi, M Gustafsson, A-C Lundstedt, I Leijonhufvud, D Karpman, B Wullt, L Truedsson, U Jodal, B Andersson, C Svanborg. Toll-Like Receptor 4 Promoter Polymorphisms: Common TLR4 Variants May Protect against Severe Urinary Tract Infection. Penha-Goncalves C, ed. PLoS ONE. 2010;5(5):e10734. doi:10.1371/journal.pone.0010734.
  9. Gágyor, I., Bleidorn, J., Kochen, M. M., Schmiemann, G., Wegscheider, K., & Hummers-Pradier, E. . Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ, 2015, 351, Art. h6544.
  10. M A J Beerepoot, S E Geerlings, E P van Haarst, N Mensing van Charante, G ter Riet, J Urol Vol 190, 2013: 1981-1989
  11. A J Stewardson, N Gaïa, P François, S Malhotra-Kumar, C Delémont, B Martinez de Tejada, J Schrenzel, S Harbarth, V Lazarevic, Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota, Clin Microbiol Infect 2015;21:344.e1-11
  12. J Vervoort J, B B Xavier, A Stewardson, S Coenen, M Godycki-Cwirko, N Adriaenssens, A Kowalczyk, C Lammens, S Harbarth, H Goossens, S Malhotra-Kumar, Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota, J Antimicrob Chemother 2015;70 :1989-92. 
  13. Robert Koch-Institut: ARS, https://ars.rki.de, Datenstand: 16.8.2016